Elpiscience Biopharma
United States
13 articles with Elpiscience Biopharma
-
Elpiscience Announces First Patient Dosed for Phase 1 Clinical Trial of First-in-Class Anti-CD39xTGF-β Bispecific Antibody ES014
2/27/2023
Elpiscience Biopharmaceuticals, Inc. today announced that the first patient has been dosed in a Phase 1 clinical trial of ES014, a first-in-class anti-CD39xTGF-β bispecific antibody (bsAb).
-
Elpiscience to Present Its Novel Immunotherapies at Biotech Showcase™ during J.P. Morgan Week 2023
1/4/2023
Elpiscience Biopharmaceuticals, Inc. today announced that it will present the latest progress of its innovative molecules and powerful antibody generation platforms at the Biotech Showcase™ conference during J.P. Morgan Week 2023 in San Francisco in January.
-
Elpiscience Announces CDE IND Clearance of ES014, a First in Class Anti-CD39xTGF-β Bispecific Antibody for Patients with Advanced Solid Tumors
12/23/2022
Elpiscience Biopharmaceuticals, Inc. announced that the Center of Drug Evaluation has cleared Elpiscience’s Investigational New Drug Application for ES014 to initiate a Phase 1 clinical study for patients with advanced solid tumors.
-
Elpiscience Announces Studies Presented at SITC 2022 Annual Meeting
11/21/2022
Elpiscience Biopharmaceuticals, Inc. presented positive studies for its innovative immunotherapeutic molecules at the SITC 2022 Annual Meeting, including anti-SIRPα monoclonal antibody ES004, PD-L1/SIRPα bispecific antibody ES019, anti-LILRB2 monoclonal antibody ES009, anti-SIGLEC15 antibody ES012, and anti-LAG3 monoclonal antibody ES005.
-
Elpiscience Announces Five Poster Presentations at Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting
10/21/2022
Elpiscience Biopharmaceuticals, Inc. today announced it will have five poster presentations at the SITC 2022 Annual Meeting being held in Boston, Massachusetts from November 8-12.
-
Achilles dosed the first patient in a Phase I/IIa advanced NSCLC trial, Logic Bio's pediatric methylmalonic acidemia study is back up and running and another look at Roche's TIGIT flop.
-
Researchers at Yale University published research in Molecular Biology and Evolution describing a new molecular analysis approach to quantify DNA changes that contribute to cancer growth.
-
Elpiscience Announces FDA IND Clearance of ES014, a First-in-Class Anti-CD39xTGF-β Bispecific Antibody for Patients with Advanced Solid Tumors
5/9/2022
Elpiscience Biopharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared Elpiscience’s ES014 Investigational New Drug (IND) Application to initiate a Phase 1 clinical study.
-
Positive Interim ES104 Phase 2 Data Reported in Combination with Paclitaxel in Biliary Tract Cancers
5/5/2022
Elpiscience Biopharmaceuticals, Inc. today announced partner Compass Therapeutics reported positive interim ES104 (also known as CTX-009) Phase 2 data in combination with paclitaxel in patients with biliary tract cancers (BTC).
-
Elpiscience Announces First Patient Dosed in Phase 1/2 Clinical Study of ES104 for Treatment of Colorectal Cancer
2/28/2022
Elpiscience Biopharmaceuticals, Inc. today announced that the first patient has been dosed in a Phase 1/2 clinical study, evaluating the safety, tolerability, pharmacokinetics and preliminary anti-tumor efficacy of ES104.
-
Elpiscience Announces CDE Clearance of IND Application for Anti-CD39 Monoclonal Antibody ES002
2/9/2022
Elpiscience Biopharmaceuticals, Inc., a global clinical-stage biopharmaceutical company dedicated to discovering and developing next-generation cancer immunotherapies, announced that the Center of Drug Evaluation has cleared Elpiscience’s Investigational New Drug Application for ES002 to initiate a Phase I clinical trial in China.
-
Elpiscience Announces First Patient Dosed in US Phase I Clinical Trial of Anti-CD39 Monoclonal Antibody ES002 for Treatment of Advanced Solid Tumors
1/20/2022
Elpiscience Biopharmaceuticals, Inc. today announced that the first patient has been dosed in a U.S. multi-center, Phase I clinical trial, evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of ES002.
-
Elpiscience to Present at the 40th Annual J.P. Morgan Healthcare Conference
1/6/2022
Elpiscience Biopharmaceuticals, Inc., a global clinical-stage biopharmaceutical company dedicated to discovering and developing next-generation cancer immunotherapies, announced that its co-founder and chief executive officer, Dr. Darren Ji, will present at the J.P. Morgan 40th Annual Healthcare Conference.